Search Result

Results for "

β-adrenergic receptor blocker

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (4) Adrenergic Receptor (45) Angiotensin Receptor (1) Antibiotic (2) Autophagy (4) Bacterial (2) Calcium Channel (8) Casein Kinase (2) Cytochrome P450 (4) Drug Derivative (1) Fungal (1) Isotope-Labeled Compounds (4) mAChR (4) NO Synthase (1) P2X Receptor (2) Peptide-Drug Conjugates (PDCs) (1) Phosphodiesterase (PDE) (1) Potassium Channel (7) Reference Standards (6) Sodium Channel (5)
By Research Areas:	Cancer (1) Cardiovascular Disease (45) Endocrinology (6) Infection (2) Inflammation/Immunology (3) Metabolic Disease (2) Neurological Disease (8)

By Targets:

5-HT Receptor (4)

Adrenergic Receptor (45)

Angiotensin Receptor (1)

Antibiotic (2)

Autophagy (4)

Bacterial (2)

Calcium Channel (8)

Casein Kinase (2)

Cytochrome P450 (4)

Drug Derivative (1)

Fungal (1)

Isotope-Labeled Compounds (4)

mAChR (4)

NO Synthase (1)

P2X Receptor (2)

Peptide-Drug Conjugates (PDCs) (1)

Phosphodiesterase (PDE) (1)

Potassium Channel (7)

Reference Standards (6)

Sodium Channel (5)

By Research Areas:

Cancer (1)

Cardiovascular Disease (45)

Endocrinology (6)

Infection (2)

Inflammation/Immunology (3)

Metabolic Disease (2)

Neurological Disease (8)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Nombre del producto	Target	Áreas de investigación	Chemical Structure

HY-B0804

Nadolol 5 Publications Verification SQ-11725	Adrenergic Receptor	Cardiovascular Disease
Nadolol (SQ-11725) is a non-selective and orally active **β-adrenergic receptors** blocker and is a substrate of organic anion transporting polypeptide 1A2 (OATP1A2). Nadolol has the the potential for high blood pressure, angina pectoris and vascular headaches research .

HY-A0016

Dronedarone 4 Publications Verification SR 33589	mAChR Sodium Channel Calcium Channel Adrenergic Receptor Cytochrome P450 Autophagy	Cardiovascular Disease
Dronedarone (SR 33589), a derivative of amiodarone (HY-14187), is a class III antiarrhythmic agent for the study of atrial fibrillation (AF) and atrial flutter. Dronedarone is a potent blocker of multiple ion currents, including potassium current, sodium current, and L-type calcium current, and exhibits antiadrenergic effects by noncompetitive binding to β-adrenergic receptors. Dronedarone is a substrate for and a moderate inhibitor of CYP3A4 .

HY-112461A

NF449 octasodium 4 Publications Verification	P2X Receptor	Cardiovascular Disease
NF449 octasodium is a highly potent P2X₁ receptor antagonist, with IC₅₀s of 0.28, 0.69, and 120 nM for rP2X₁, rP2X₁₊₅, P2X₂₊₃, respectively. NF449 octasodium is a G_sα-selective G Protein antagonist. NF449 octasodium suppresses the rate of GTP[γS] binding to G_sα-s, inhibits the stimulation of adenylyl cyclase activity, and blocks the coupling of β-adrenergic receptors to G_s .

HY-B0437

Sotalol hydrochloride 2 Publications Verification MJ 1999	Adrenergic Receptor Potassium Channel	Cardiovascular Disease Neurological Disease
Sotalol hydrochloride (MJ 1999) is an orally active, non-selective **β-adrenergic receptor** blocker. Sotalol hydrochloride is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol hydrochloride blocks β-receptors, and potassium KCNH2 channels. Antiepileptic Agent .

HY-100634

4-Hydroxypropranolol hydrochloride (±)-4-hydroxy Propranolol hydrochloride	Adrenergic Receptor	Cardiovascular Disease
4-Hydroxypropranolol hydrochloride is a non-cardiac selective **β-adrenergic receptor** antagonist and a metabolite produced after oral administration of Propranolol (HY-B0573B). 4-Hydroxypropranolol hydrochloride also acts as a membrane stabilizer and possesses intrinsic sympathomimetic inhibitory activity. 4-Hydroxypropranolol hydrochloride blocks β-adrenergic receptors to antagonize the effects of catecholamines, acts as a partial β-adrenergic receptor agonist, and induces membrane stabilization. 4-Hydroxypropranolol hydrochloride alters heart rate, left ventricular contractility, and atrioventricular conduction time. 4-Hydroxypropranolol hydrochloride can be used in research related to cardiovascular and cerebrovascular diseases .

HY-112461

NF449	P2X Receptor	Cardiovascular Disease
NF449 is a highly potent P2X₁ receptor antagonist, with IC₅₀s of 0.28, 0.69, and 120 nM for rP2X₁, rP2X₁₊₅, P2X₂₊₃, respectively. NF449 is a G_sα-selective G Protein antagonist. NF449 suppresses the rate of GTP[γS] binding to G_sα-s, inhibits the stimulation of adenylyl cyclase activity, and blocks the coupling of β-adrenergic receptors to G_s .

HY-B1035

Levobunolol hydrochloride 1 Publications Verification l-Bunolol hydrochloride	Adrenergic Receptor Calcium Channel Casein Kinase	Cardiovascular Disease
Levobunolol (l-Bunolol) hydrochloride is a non-selective *β-adrenergic* antagonist and vasodilator. By blocking calcium ion influx and reducing the sensitivity of vascular smooth muscle to calcium, Levobunolol hydrochloride effectively dilates the ciliary arteries and increases ocular blood flow, so it is widely used in research on glaucoma and ocular hypertension. Levobunolol hydrochloride inhibits the β-receptor signaling pathway and the expression of related proliferation markers (such as CK3, CK14, CK19, Ki67) in corneal cells. In rabbit models, Levobunolol hydrochloride not only does not inhibit corneal epithelial regeneration, but also accelerates the healing of mechanical injury without adverse effects. Levobunolol hydrochloride also inhibits histamine-induced vasoconstriction and intracellular calcium elevation, exhibiting unique vascular regulatory activity. Levobunolol hydrochloride protects ocular blood flow and promotes corneal repair .

HY-122537A

Arotinolol 2 Publications Verification	Adrenergic Receptor 5-HT Receptor	Cardiovascular Disease
Arotinolol is a nonselective α/β-adrenergic receptor blocker and a vasodilating β-blocker . Arotinolol also shows potency for inhibiting the binding of the radioligand ¹²⁵I-ICYP to 5HT_1B-serotonergic receptor sites . Arotinolol is an antihypertensive agent for the treatment of a variety of cardiovascular pathologies as well as non-cardiovascular diseases .

HY-126028A

(+)-Sotalol (S)-Sotalol	Adrenergic Receptor	Cardiovascular Disease Neurological Disease
(+)-Sotalol ((S)-Sotalol) is the S-isomer of Sotalol (HY-103196). Sotalol is an orally active, non-selective **β-adrenergic receptor** blocker. (+)-Sotalol is an antiarrhythmic agent. (+)-Sotalol can prolong action potential duration in isolated cardiac muscle .

HY-101656

Medroxalol RMI81968	Adrenergic Receptor	Cardiovascular Disease
Medroxalol (RMI81968) is an orally active **adrenergic receptor** antagonist, blocks α- and β-adrenergic receptors. Medroxalol shows antihypertensive and vasodilating effects .

HY-B0437AS

Sotalol-d6 hydrochloride MJ 1999-d6 hydrochloride	Adrenergic Receptor Potassium Channel	Cardiovascular Disease Endocrinology
Sotalol-d₆ (hydrochloride) is a deuterium labeled Sotalol hydrochloride. Sotalol hydrochloride is an orally active, non-selective competitive β-adrenergic receptor blocker. Sotalol hydrochloride is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol hydrochloride blocks β-receptors, and potassium KCNH2 channels .

HY-16316

Metipranolol hydrochloride 1 Publications Verification	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Metipranolol hydrochloride is a non-selective **β adrenergic receptor** blocking agent.

HY-121045

Bunitrolol KO 1366	Adrenergic Receptor	Cardiovascular Disease
Bunitrolol hydrochloride is an orally active β-adrenergic blocker that has a high affinity for **β-adrenergic receptors*. Bunitrolol hydrochloride exerts significant β-receptor* antagonist activity and has weak α₁-blocking activity. Bunitrolol hydrochloride is mainly used in the study of cardiovascular diseases such as hypertension and angina pectoris, and is also used in placental transport research .

HY-B0381B

Levobetaxolol hydrochloride (S)-Betaxolol hydrochloride; AL-1577A	Adrenergic Receptor	Cardiovascular Disease Neurological Disease Endocrinology
Levobetaxolol hydrochloride is a beta-adrenergic receptor inhibitor (beta blocker) that can lower the pressure in the eye.

HY-105154A

Proxodolol	Adrenergic Receptor	Cardiovascular Disease
Proxodolol is a **β-adrenergic receptor** blocker. Proxodolol can be used for the study of arterial hypertension .

HY-B0804S

Nadolol-d9 SQ-11725-d₉	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Nadolol-d₉ is the deuterium labeled Nadolol. Nadolol is a non-selective and orally active β-adrenergic receptors blocker .

HY-103196

Sotalol	Adrenergic Receptor Potassium Channel	Cardiovascular Disease Neurological Disease
Sotalol is an orally active, non-selective **β-adrenergic receptor** blocker. Sotalol is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol blocks β-receptors, and potassium KCNH2 channels. Antiepileptic Agent .

HY-100952

Nifenalol hydrochloride	Adrenergic Receptor	Cardiovascular Disease
Nifenalol hydrochloride is a **β-adrenergic receptor** antagonist. Nifenalol hydrochloride induces the Early Afterdepolarization (EAD) effect. EAD is a phenomenon in cardiac electrophysiology that usually occurs during an action potential in ventricular muscle cells and can lead to arrhythmia. The EAD effect of Nifenalol hydrochloride can be blocked by Tetrodotoxin. Nifenalol hydrochloride is used in the study of conditions such as irregular heartbeat or high blood pressure .

HY-B0804R

Nadolol (Standard) SQ-11725 (Standard)	Reference Standards Adrenergic Receptor	Cardiovascular Disease
Nadolol (Standard) is the analytical standard of Nadolol. This product is intended for research and analytical applications. Nadolol (SQ-11725) is a non-selective and orally active **β-adrenergic receptors** blocker and is a substrate of organic anion transporting polypeptide 1A2 (OATP1A2). Nadolol has the the potential for high blood pressure, angina pectoris and vascular headaches research .

HY-A0016S

Dronedarone-d6 hydrochloride	Isotope-Labeled Compounds mAChR Sodium Channel Calcium Channel Adrenergic Receptor Cytochrome P450 Autophagy	Cardiovascular Disease
Dronedarone-d₆ (hydrochloride) is the deuterium labeled Dronedarone. Dronedarone hydrochloride, a derivative of Amiodarone (HY-14187), is a class III antiarrhythmic agent for the study of atrial fibrillation (AF) and atrial flutter. Dronedarone hydrochloride is a potent blocker of multiple ion currents, including potassium current, sodium current, and L-type calcium current, and exhibits antiadrenergic effects by noncompetitive binding to β-adrenergic receptors. Dronedarone hydrochloride is a substrate for and a moderate inhibitor of CYP3A4 .

HY-122537

Arotinolol hydrochloride	Adrenergic Receptor 5-HT Receptor	Cardiovascular Disease
Arotinolol hydrochloride is a nonselective α/β-adrenergic receptor blocker and a vasodilating β-blocker . Arotinolol hydrochloride also shows potency for inhibiting the binding of the radioligand ¹²⁵I-ICYP to 5HT_1B-serotonergic receptor sites . Arotinolol hydrochloride is an antihypertensive agent for the treatment of a variety of cardiovascular pathologies as well as non-cardiovascular diseases .

HY-U00016

Teoprolol	Adrenergic Receptor	Endocrinology
Teoprolol is a **β-adrenergic receptor** blocker.

HY-101656A

Medroxalol hydrochloride RMI81968 hydrochloride	Adrenergic Receptor	Cardiovascular Disease
Medroxalol hydrochloride is an orally active **adrenergic receptor** antagonist, blocks α- and β-adrenergic receptors. Medroxalol hydrochloride shows antihypertensive and vasodilating effects .

HY-108302

Nifenalol	Adrenergic Receptor	Others
Nifenalol is a **β-adrenergic receptor** blocker. Nifenalol inhibits β-adrenoceptor differentiation in right atrium, diaphragm and adipose tissue in a rat model .

HY-178319

Photoazolol-1 PZL-1	Drug Derivative Adrenergic Receptor	Cardiovascular Disease
Photoazolol-1 is a **β-adrenergic receptor** (βAR)-blocker derivative. Photoazolol-1 can transfer from an inverse agonist to a neutral antagonist upon photoactivation .

HY-P10773

CTP-amiodarone	Peptide-Drug Conjugates (PDCs) Calcium Channel Potassium Channel Sodium Channel Adrenergic Receptor	Cardiovascular Disease
CTP-amiodarone is a cell-penetrating conjugate of cardiomyocyte targeting peptide and Amiodarone (HY-14187). CTP-amiodarone exhibits antiarrhythmic efficacy through block of Na+, K+, Ca2+ channels and β-adrenergic receptors .

HY-B0437S

Sotalol-d6 MJ 1999-d₆	Isotope-Labeled Compounds Adrenergic Receptor Potassium Channel	Cardiovascular Disease Neurological Disease
Sotalol-d₆ is the deuterium labeled Sotalol. Sotalol is an orally active, non-selective β-adrenergic receptor blocker. Sotalol is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol blocks β-receptors, and potassium KCNH2 channels. Antiepileptic Agent .

HY-B0437R

Sotalol hydrochloride (Standard) MJ 1999 (Standard)	Reference Standards Adrenergic Receptor Potassium Channel	Cardiovascular Disease Neurological Disease
Sotalol (hydrochloride) (Standard) is the analytical standard of Sotalol (hydrochloride). This product is intended for research and analytical applications. Sotalol hydrochloride (MJ 1999) is an orally active, non-selective β-adrenergic receptor blocker. Sotalol hydrochloride is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol hydrochloride blocks β-receptors, and potassium KCNH2 channels. Antiepileptic Agent .

HY-126562R

Piperlonguminine (Standard)	Reference Standards Bacterial Fungal Antibiotic	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Sotalol (hydrochloride) (Standard) is the analytical standard of Sotalol (hydrochloride). This product is intended for research and analytical applications. Sotalol hydrochloride (MJ 1999) is an orally active, non-selective β-adrenergic receptor blocker. Sotalol hydrochloride is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol hydrochloride blocks β-receptors, and potassium KCNH2 channels. Antiepileptic Agent .

HY-B1035C

ent-Levobunolol hydrochloride (R)-Bunolol hydrochloride	Adrenergic Receptor	Cardiovascular Disease
ent-Levobunolol ((R)-Bunolol) hydrochloride is a competitive **β-adrenergic receptor** blocker. ent-Levobunolol hydrochloride inhibits the transmission of sympathetic nerve impulses, reduces the production of aqueous humor, and constricts blood vessels in the eye, thereby reducing intraocular pressure. ent-Levobunolol hydrochloride is promising for research of ocular hypertension diseases such as glaucoma .

HY-19022

BW A256C	Angiotensin Receptor	Cardiovascular Disease Others Metabolic Disease
Palatrigine is a compound with angiotensin-converting enzyme inhibitory and beta-adrenergic receptor blocking properties .

HY-108306

Moprolol (±)-Moprolol	Adrenergic Receptor	Cardiovascular Disease Others
Moprolol ((±)-Moprolol) is an **beta-adrenergic receptor** blocker, which can be used for research in essential hypertension .

HY-A0016R

Dronedarone (Standard) SR 33589 (Standard)	Reference Standards mAChR Sodium Channel Calcium Channel Adrenergic Receptor Cytochrome P450 Autophagy	Cardiovascular Disease
Dronedarone (Standard) is the analytical standard of Dronedarone. This product is intended for research and analytical applications. Dronedarone (SR 33589), a derivative of amiodarone (HY-14187), is a class III antiarrhythmic agent for the study of atrial fibrillation (AF) and atrial flutter. Dronedarone is a potent blocker of multiple ion currents, including potassium current, sodium current, and L-type calcium current, and exhibits antiadrenergic effects by noncompetitive binding to β-adrenergic receptors. Dronedarone is a substrate for and a moderate inhibitor of CYP3A4 .

HY-117181

UK-1745	Phosphodiesterase (PDE) Adrenergic Receptor	Cardiovascular Disease
UK-1745 is a cardiotonic agent with vasodilating and antiarrhythmic properties. It increases intracellular levels of cyclic adenosine monophosphate (cAMP) in cardiomyocytes by inhibiting phosphodiesterase III, thereby enhancing myocardial contractility. Additionally, UK-1745 exhibits **β-adrenergic receptor** blocking activity, which helps reduce the oxygen consumption of the heart and prevent calcium overload. These characteristics make UK-1745 a promising candidate for research in congestive heart failure .

HY-113858

Brefonalol Brefanolol	Adrenergic Receptor	Cardiovascular Disease
Brefonalol (Brefanolol) is an orally active, non-selective **β-adrenergic receptor** blocker with vasodilatory properties. Brefonalol exhibits an optimal balance between β-blockade and vasodilatory effects at low doses: it reduces blood pressure and slows heart rate, while increasing stroke volume instead of decreasing it, causing no significant elevation in peripheral resistance and increasing reactive hyperemia; at high doses, the β-blockade effect dominates. Brefonalol can be used in the research of arterial hypertension .

HY-A0016S3

Dronedarone-d6 SR 33589-d₆	Isotope-Labeled Compounds Sodium Channel Autophagy Cytochrome P450 Adrenergic Receptor mAChR Calcium Channel	Cardiovascular Disease
Dronedarone-d₆ (SR 33589-d₆) is deuterium labeled Dronedarone. Dronedarone (SR 33589), a derivative of amiodarone (HY-14187), is a class III antiarrhythmic agent for the study of atrial fibrillation (AF) and atrial flutter. Dronedarone is a potent blocker of multiple ion currents, including potassium current, sodium current, and L-type calcium current, and exhibits antiadrenergic effects by noncompetitive binding to β-adrenergic receptors. Dronedarone is a substrate for and a moderate inhibitor of CYP3A4 .

HY-121902

Butidrine	Adrenergic Receptor	Others
Butidrine is a compound with intraocular pressure-lowering activity that is less effective than some other beta-adrenergic receptor blockers in reducing intraocular pressure in rabbit eyes.

HY-106476

Primidolol UK-11443	Adrenergic Receptor Bacterial Antibiotic	Infection Cardiovascular Disease
Primidolol (UK-11443), derived from Parmotrema perlatum, possesses antibacterial and antioxidant activities. Primidolol is also an orally active α/β Adrenergic Receptor blocker with antihypertensive activity. Primidolol can be used in research related to infections and cardiovascular diseases .

HY-19012

N-1518	Adrenergic Receptor	Cardiovascular Disease
N-1518 is an α and β adrenergic receptor blocker that has competitive antagonism against β1 and α1 receptors, but does not show selectivity for β1 receptors, but shows about 20-fold selectivity for α1 receptors. N-1518 has vasodilatory effects and can be used in the research field of hypertension treatment .

HY-106667

DL 071IT	Adrenergic Receptor	Cardiovascular Disease Endocrinology
DL 071IT is a potent non-selective beta-adrenergic *receptor* blocker. DL 071IT exhibits intrinsic sympathomimetic activity and weak membrane stabilizing activity. DL 071IT reduces exercise heart rate and systolic blood pressure, and even significantly lowers resting heart rate .

HY-W653969

Arotinolol-d5 hydrochloride	Isotope-Labeled Compounds Adrenergic Receptor 5-HT Receptor	Cardiovascular Disease
Arotinolol-d₅ (hydrochloride) is deuterium labeled Arotinolol. Arotinolol is a nonselective α/β-adrenergic receptor blocker and a vasodilating β-blocker . Arotinolol also shows potency for inhibiting the binding of the radioligand ¹²⁵I-ICYP to 5HT_1B-serotonergic receptor sites. Arotinolol is an antihypertensive agent for the treatment of a variety of cardiovascular pathologies as well as non-cardiovascular diseases .

HY-122537AR

Arotinolol (Standard)	Adrenergic Receptor 5-HT Receptor Reference Standards	Cardiovascular Disease
Arotinolol (Standard) is the analytical standard of Arotinolol. This product is intended for research and analytical applications. Arotinolol is a nonselective α/β-adrenergic receptor blocker and a vasodilating β-blocker . Arotinolol also shows potency for inhibiting the binding of the radioligand 125I-ICYP to 5HT1B-serotonergic receptor sites . Arotinolol is an antihypertensive agent for the treatment of a variety of cardiovascular pathologies as well as non-cardiovascular diseases .

HY-B1035A

Levobunolol l-Bunolol	Adrenergic Receptor Casein Kinase Calcium Channel	Others
Levobunolol (l-Bunolol) is a non-selective *β-adrenergic* antagonist and vasodilator. By blocking calcium ion influx and reducing the sensitivity of vascular smooth muscle to calcium, Levobunolol effectively dilates the ciliary arteries and increases ocular blood flow, so it is widely used in research on glaucoma and ocular hypertension. Levobunolol inhibits the β-receptor signaling pathway and the expression of related proliferation markers (such as CK3, CK14, CK19, Ki67) in corneal cells. In rabbit models, Levobunolol not only does not inhibit corneal epithelial regeneration, but also accelerates the healing of mechanical injury without adverse effects. Levobunolol also inhibits histamine-induced vasoconstriction and intracellular calcium elevation, exhibiting unique vascular regulatory activity. Levobunolol protects ocular blood flow and promotes corneal repair .

HY-116957

Bunitrolol hydrochloride	Adrenergic Receptor	Cardiovascular Disease
Bunitrolol hydrochloride is an orally active β-adrenergic blocker that has a high affinity for **β-adrenergic receptors*. Bunitrolol hydrochloride exerts significant β-receptor* antagonist activity and has weak α₁-blocking activity. Bunitrolol hydrochloride is mainly used in the study of cardiovascular diseases such as hypertension and angina pectoris, and is also used in placental transport research .

HY-105154

Proxodolol free base	Adrenergic Receptor	Cardiovascular Disease
Proxodolol free base is a **β-adrenergic receptor** blocker. Proxodolol free base can be used for the study of arterial hypertension .

HY-101656R

Medroxalol (Standard) RMI81968 (Standard)	Adrenergic Receptor Reference Standards	Cardiovascular Disease
Medroxalol (Standard) is the analytical standard of Medroxalol (HY-101656). This product is intended for research and analytical applications. Medroxalol (RMI81968) is an orally active adrenergic receptor antagonist, blocks α- and β-adrenergic receptors. Medroxalol shows antihypertensive and vasodilating effects .

HY-B1562D

(S)-Bopindolol	Adrenergic Receptor	Metabolic Disease
(S)-Bopindolol is a **β-adrenergic receptor** blocker that can be used to prevent, inhibit, can be used to reduce muscle mass and/or functional loss and/or decreased bone density caused by weight loss. (S)-Bopindolol can protect the myocardium and/or cardiac function, or prevent low blood pressure and/or increased heart rate during weight loss .

HY-114833

Bunolol (Rac)-Bunolol; dl-Bunolol	Adrenergic Receptor	Cardiovascular Disease Neurological Disease
Bunolol ((Rac)-Bunolol) is a **β-adrenergic receptor** blocker. Bunolol antagonizes the β-receptor agonist activity induced by Isoproterenol (HY-B0468) and Dichloroisoproterenol. Bunolol reduces the heart rate and mean blood pressure of anesthetized dogs. Bunolol decreases spontaneous motor activity and Amphetamine-induced hyperactivity in rats, potentiates Pentobarbital-induced hypnosis in mice, and protects rats from extensor tonic convulsions induced by maximal electroshock .

HY-181755

Phenylaminojuglone AJ-2	NO Synthase	Inflammation/Immunology
Phenylaminojuglone AJ-2 is a nitric oxide synthase inhibitor that interacts with soluble guanylate cyclase, β-adrenergic receptor, CaV1.2 calcium channel, KV channel and KCa channel. Phenylaminojuglone AJ-2 blocks extracellular Ca ²⁺ influx, regulates the activity of the NO?sGC?cGMP signaling pathway, and inhibits pharmacologic and electromechanical contractions of smooth muscle. Phenylaminojuglone AJ-2 is applicable to studies related to intestinal spasm .

HY-113858A

Brefonalol (hydrochloride) Brefanolol hydrochloride	Adrenergic Receptor	Cardiovascular Disease
Brefonalol (Brefanolol) hydrochloride is an orally active, non-selective **β-adrenergic receptor** blocker with vasodilatory properties. Brefonalol hydrochloride exhibits an optimal balance between β-blockade and vasodilatory effects at low doses: it reduces blood pressure and slows heart rate, while increasing stroke volume instead of decreasing it, causing no significant elevation in peripheral resistance and increasing reactive hyperemia; at high doses, the β-blockade effect dominates. Brefonalol hydrochloride can be used in the research of arterial hypertension .

Cat. No.	Nombre del producto	Category	Target	Chemical Structure

HY-126562R

Piperlonguminine (Standard)	Alkaloids Structural Classification Capsicum annuum L. Other Alkaloids Solanaceae Plants Source Classification	Reference Standards Bacterial Fungal Antibiotic
Sotalol (hydrochloride) (Standard) is the analytical standard of Sotalol (hydrochloride). This product is intended for research and analytical applications. Sotalol hydrochloride (MJ 1999) is an orally active, non-selective β-adrenergic receptor blocker. Sotalol hydrochloride is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol hydrochloride blocks β-receptors, and potassium KCNH2 channels. Antiepileptic Agent .

Cat. No.	Nombre del producto	Chemical Structure

HY-B0437AS

Sotalol-d6 hydrochloride
Sotalol-d₆ (hydrochloride) is a deuterium labeled Sotalol hydrochloride. Sotalol hydrochloride is an orally active, non-selective competitive β-adrenergic receptor blocker. Sotalol hydrochloride is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol hydrochloride blocks β-receptors, and potassium KCNH2 channels .

HY-B0804S

Nadolol-d9
Nadolol-d₉ is the deuterium labeled Nadolol. Nadolol is a non-selective and orally active β-adrenergic receptors blocker .

HY-A0016S

Dronedarone-d6 hydrochloride

Dronedarone-d₆ (hydrochloride) is the deuterium labeled Dronedarone. Dronedarone hydrochloride, a derivative of Amiodarone (HY-14187), is a class III antiarrhythmic agent for the study of atrial fibrillation (AF) and atrial flutter. Dronedarone hydrochloride is a potent blocker of multiple ion currents, including potassium current, sodium current, and L-type calcium current, and exhibits antiadrenergic effects by noncompetitive binding to β-adrenergic receptors. Dronedarone hydrochloride is a substrate for and a moderate inhibitor of CYP3A4 .

HY-B0437S

Sotalol-d6
Sotalol-d₆ is the deuterium labeled Sotalol. Sotalol is an orally active, non-selective β-adrenergic receptor blocker. Sotalol is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol blocks β-receptors, and potassium KCNH2 channels. Antiepileptic Agent .

HY-A0016S3

Dronedarone-d6

Dronedarone-d₆ (SR 33589-d₆) is deuterium labeled Dronedarone. Dronedarone (SR 33589), a derivative of amiodarone (HY-14187), is a class III antiarrhythmic agent for the study of atrial fibrillation (AF) and atrial flutter. Dronedarone is a potent blocker of multiple ion currents, including potassium current, sodium current, and L-type calcium current, and exhibits antiadrenergic effects by noncompetitive binding to β-adrenergic receptors. Dronedarone is a substrate for and a moderate inhibitor of CYP3A4 .

HY-W653969

Arotinolol-d5 hydrochloride

Arotinolol-d₅ (hydrochloride) is deuterium labeled Arotinolol. Arotinolol is a nonselective α/β-adrenergic receptor blocker and a vasodilating β-blocker . Arotinolol also shows potency for inhibiting the binding of the radioligand ¹²⁵I-ICYP to 5HT_1B-serotonergic receptor sites. Arotinolol is an antihypertensive agent for the treatment of a variety of cardiovascular pathologies as well as non-cardiovascular diseases .

Consulta en línea

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Saludo			Country or Region *
Nombre del solicitante *			Nombre de la Organizaciòn *
Department *
Direcciòn del E-mail *			Nombre del producto *
Cat. No.			Requested quantity *
Número de teléfono *
Observaciones